Comparing the Efficacy and Safety of Adalimumab and Vedolizumab in Treating Moderate to Severe Crohn's Disease and Ulcerative Colitis Article (Faculty180)

cited authors

  • Merza, Nooraldin; Nawras, Yusuf; Saab, Omar; Dahiya, Dushyant Sing S; Ahmed, Zohaib; Ranabothu, Meghana; Boujemaa, Safa; Hassan, Mona; Kobeissy, Abdallah; Lilley, Kirthi

description

  • Numerous patients with inflammatory bowel disease (IBD) do not respond to conventional or biological therapy. Adalimumab (ADA) and vedolizumab (VDZ), according to certain research, may be a useful alternative treatment for these people. The purpose of this study was to assess the effectiveness and safety of using ADA and VDZ to treat moderate to severe IBD: Crohn's disease (CD) and ulcerative colitis (UC).

authors

publication date

  • 2023

published in

start page

  • 289

end page

  • 306

volume

  • 16